Anika Therapeutics saw the highest growth of 299% in patent filings in October and 399% in grants in November in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 299% and grants by 32%. GlobalData’s DataBook provides a comprehensive analysis of Anika Therapeutics‘s patent filings and grants. Buy the databook here.
Anika Therapeutics has been focused on protecting inventions in European Patent Office(EPO) with one publication in Q4 2023
The United States(US), and European Patent Office(EPO) patent Office are among the top ten patent offices where Anika Therapeutics is filings its patents.
Johnson & Johnson could be the strongest competitor for Anika Therapeutics
In terms of grant share, Anika Therapeutics stands in fourth position among its competitors. Johnson & Johnson and Anika Therapeutics secured the top positions according to recent patent publication data.
Orthopedic devices related patents lead Anika Therapeutics portfolio followed by sutures, and general surgery devices
Anika Therapeutics has highest number of patents in orthopedic devices followed by sutures, general surgery devices, medical device, and rheumatoid arthritis. For orthopedic devices, nearly 64% of patents were filed and 83% of patents were granted in Q4 2023.